Imunon, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Imunon, Inc. (IMNN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 7.50 thousand shares for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-11.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2018-05-11
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2018-03-31 was 7.50K shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2017-12-31 was 22.50K shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2017-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2016-12-31 was -780.83K shares, a 700.64% decline year-over-year.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2017 was 535.96K shares, a 786.64% increase from fiscal 2016.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2016 was 60.45K shares, a 92.80% decline from fiscal 2015.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2015 was 839.25K shares, a 17.29% decline from fiscal 2014.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2014 was 1.01M shares, a 440.38% increase from fiscal 2013.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month as first filed |
|---|---|---|---|---|---|
| 2018-03-31 | 7.50K shares 10-Q · filed 2018-05-11 | 30.00K shares derived: sum of 2 quarters · filed 2018-05-11 | 30.00K shares derived: sum of 3 quarters · filed 2018-05-11 | ||
| 2017-12-31 | 22.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-27 | 22.50K shares derived: sum of 2 quarters · filed 2018-03-27 | 535.96K shares 10-K · filed 2018-03-27 | ||
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | 513.46K shares 10-Q · filed 2017-11-14 | |||
| 2017-06-30 | 513.46K shares 10-Q · filed 2017-08-14 | ||||
| 2016-12-31 | -780.83K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-27 | -490.80K shares derived: sum of 2 quarters · filed 2018-03-27 | -490.80K shares derived: sum of 3 quarters · filed 2018-03-27 | 60.45K shares 10-K · filed 2018-03-27 | 846.28K shares 10-K · filed 2017-03-24 |
| 2016-09-30 | 290.03K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | 290.03K shares derived: sum of 2 quarters · filed 2016-11-10 | 841.28K shares 10-Q · filed 2016-11-10 | 971.28K shares derived: sum of 4 quarters · filed 2017-03-24 | |
| 2016-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | 551.25K shares 10-Q · filed 2016-08-15 | 681.25K shares derived: sum of 3 quarters · filed 2017-03-24 | 681.25K shares derived: sum of 4 quarters · filed 2017-03-24 | |
| 2016-03-31 | 551.25K shares 10-Q · filed 2016-05-16 | 681.25K shares derived: sum of 2 quarters · filed 2017-03-24 | 681.25K shares derived: sum of 3 quarters · filed 2017-03-24 | 772.75K shares derived: sum of 4 quarters · filed 2017-03-24 | |
| 2015-12-31 | 130.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | 130.00K shares derived: sum of 2 quarters · filed 2017-03-24 | 221.50K shares derived: sum of 3 quarters · filed 2017-03-24 | 839.25K shares 10-K · filed 2017-03-24 | |
| 2015-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | 91.50K shares derived: sum of 2 quarters · filed 2015-11-05 | 709.25K shares 10-Q · filed 2015-11-05 | ||
| 2015-06-30 | 91.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | 709.25K shares 10-Q · filed 2015-08-10 | |||
| 2015-03-31 | 617.75K shares 10-Q · filed 2015-05-11 | ||||
| 2014-12-31 | 1.01M shares 10-K · filed 2016-03-30 | ||||
| 2014-06-30 | 722.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | 1.05M shares 10-Q · filed 2014-08-07 | |||
| 2014-03-31 | 323.20K shares 10-Q · filed 2014-05-08 | ||||
| 2013-12-31 | 187.78K shares 10-K · filed 2016-03-30 | ||||
| 2012-12-31 | 145.61K shares 10-K · filed 2015-03-12 | 655.25K shares 10-K · filed 2013-03-18 | |||
| 2011-12-31 | 265.70K shares 10-K · filed 2014-03-13 | 1.20M shares 10-K · filed 2013-03-18 | |||
| 2010-12-31 | 656.50K shares 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |